Literature DB >> 2535829

Refractory ascites due to POEMS syndrome.

J M Loeb1, P H Hauger, J D Carney, A D Cooper.   

Abstract

A 52-yr-old woman developed exudative ascites 2 yr after the onset of peripheral neuropathy. Extensive evaluation revealed that the patient had no underlying liver disease, malignancy, infection, or cardiac or renal disease. The ascites initially responded to high-dose corticosteroid therapy. The patient had many clinical features of the recently described POEMS syndrome, including a persistent IgA lambda-paraprotein. Initially, her ascites responded to treatment with steroids. This is characteristic of the syndrome and should be considered in patients with POEMS syndrome and refractory ascites.

Entities:  

Mesh:

Year:  1989        PMID: 2535829     DOI: 10.1016/0016-5085(89)90789-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  4 in total

Review 1.  Portal hypertension and refractory ascites associated with multicentric Castleman's disease.

Authors:  M Abarca; R J Andrade; A García-Arjona; J L Escolar; A Blanes; J M García-Hirschfeld; P González-Santos
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

2.  Coexistence of the POEMS syndrome with hepatitis B: a rare case report.

Authors:  Yılmaz Celik; Mehmet Aslan; Refah Sayın; Adem Cifci; Esra Turan Canbaz; Mehmet Emin Kucukoglu; Ahmet Cumhur Dulger
Journal:  Wien Klin Wochenschr       Date:  2014-11-21       Impact factor: 1.704

3.  Lenalidomide and Dexamethasone for a Patient of POEMS Syndrome Presenting with Massive Ascites.

Authors:  Shuji Ueda; Sayoko Yonemoto; Kazumasa Oka; Naohiko Fujii; Keiichi Nakata; Hitomi Matsunaga; Seiko Kataoka; Yuki Iwama; Hiroyuki Narahara; Yuichi Yasunaga; Yoshiaki Inui; Sumio Kawata
Journal:  Case Rep Hematol       Date:  2014-02-19

Review 4.  Cytokines in Endocrine Dysfunction of Plasma Cell Disorders.

Authors:  Eva Feigerlová; Shyue-Fang Battaglia-Hsu
Journal:  Mediators Inflamm       Date:  2017-06-27       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.